Hua Medicine (Shanghai) Future Growth
Future criteria checks 5/6
Hua Medicine (Shanghai) is forecast to grow earnings and revenue by 83.3% and 85.9% per annum respectively. EPS is expected to grow by 83.1% per annum. Return on equity is forecast to be 11% in 3 years.
Key information
83.3%
Earnings growth rate
83.1%
EPS growth rate
| Pharmaceuticals earnings growth | 12.7% |
| Revenue growth rate | 85.9% |
| Future return on equity | 11.0% |
| Analyst coverage | Low |
| Last updated | 19 Sep 2023 |
Recent future growth updates
Recent updates
Is Hua Medicine (Shanghai) (HKG:2552) Using Too Much Debt?
Nov 17
Investors Appear Satisfied With Hua Medicine (Shanghai) Ltd.'s (HKG:2552) Prospects
Aug 28We Think Hua Medicine (Shanghai) (HKG:2552) Can Afford To Drive Business Growth
Jan 06We're Interested To See How Hua Medicine (Shanghai) (HKG:2552) Uses Its Cash Hoard To Grow
Aug 02Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth
Apr 22Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth
Sep 23We're Not Worried About Hua Medicine (Shanghai)'s (HKG:2552) Cash Burn
Jun 24Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth
Mar 22Hua Medicine (Shanghai) Ltd.'s (HKG:2552) Profit Outlook
Feb 21Hua Medicine (Shanghai) (HKG:2552) Shareholders Booked A 21% Gain In The Last Year
Jan 25
Hua Medicine (Shanghai) (HKG:2552) Is In A Strong Position To Grow Its Business
Dec 21Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 1,079 | 81 | N/A | 176 | 2 |
| 12/31/2024 | 594 | -233 | N/A | 34 | 2 |
| 12/31/2023 | 77 | -211 | 889 | 889 | N/A |
| 9/30/2023 | 91 | -200 | 502 | 517 | N/A |
| 6/30/2023 | 88 | -189 | 115 | 145 | N/A |
| 3/31/2023 | 53 | -196 | -71 | -42 | N/A |
| 12/31/2022 | 18 | -204 | -258 | -230 | N/A |
| 9/30/2022 | 0 | -234 | -250 | -228 | N/A |
| 6/30/2022 | 0 | -265 | -243 | -225 | N/A |
| 3/31/2022 | 0 | -295 | -271 | -249 | N/A |
| 12/31/2021 | N/A | -326 | -300 | -273 | N/A |
| 9/30/2021 | 4 | -355 | -178 | -145 | N/A |
| 6/30/2021 | 9 | -385 | -56 | -18 | N/A |
| 3/31/2021 | 9 | -389 | -51 | -19 | N/A |
| 12/31/2020 | 9 | -393 | -47 | -21 | N/A |
| 9/30/2020 | 16 | -378 | -182 | -166 | N/A |
| 6/30/2020 | 23 | -363 | -318 | -311 | N/A |
| 3/31/2020 | 22 | -394 | -335 | -327 | N/A |
| 12/31/2019 | 22 | -425 | -352 | -342 | N/A |
| 9/30/2019 | 12 | -1,379 | -354 | -344 | N/A |
| 6/30/2019 | 3 | -2,333 | -356 | -347 | N/A |
| 3/31/2019 | 3 | -3,399 | -309 | -302 | N/A |
| 12/31/2018 | 9 | -3,603 | -275 | -269 | N/A |
| 9/30/2018 | 13 | -2,578 | -266 | -262 | N/A |
| 6/30/2018 | 17 | -1,554 | -257 | -255 | N/A |
| 3/31/2018 | 16 | -440 | -245 | -242 | N/A |
| 12/31/2017 | 11 | -273 | -201 | -199 | N/A |
| 12/31/2016 | 1 | -361 | N/A | -76 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2552 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: 2552 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 2552 is expected to become profitable in the next 3 years.
Revenue vs Market: 2552's revenue (85.9% per year) is forecast to grow faster than the Hong Kong market (8.2% per year).
High Growth Revenue: 2552's revenue (85.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2552's Return on Equity is forecast to be low in 3 years time (11%).